Harmony Biosciences Holdings (HRMY) Long-Term Investments (2022 - 2026)

Harmony Biosciences Holdings (HRMY) has 5 years of Long-Term Investments data on file, last reported at $229.6 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 122.34% year-over-year to $229.6 million; the trailing twelve-month figure through Mar 2026 stood at $229.6 million (up 122.34% YoY), and the FY2025 full-year result was $107.1 million, down 1.6% from the prior year.
• Long-Term Investments grew to $229.6 million in Q1 2026, from $107.1 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $229.6 million in Q1 2026 to a low of $4.7 million in Q2 2022.
• A 5-year average of $81.7 million and a median of $84.2 million in 2024 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments surged 1135.54% in 2023 and declined 1.6% in 2025, its largest moves.
• Tracing HRMY's Long-Term Investments over 5 years: stood at $22.6 million in 2022, then jumped by 219.78% to $72.2 million in 2023, then soared by 50.86% to $108.9 million in 2024, then dropped by 1.6% to $107.1 million in 2025, then surged by 114.28% to $229.6 million in 2026.
• Business Quant data shows HRMY's Long-Term Investments at $229.6 million in Q1 2026, $107.1 million in Q4 2025, and $105.8 million in Q3 2025.